← back to search

Jake Y. Henry

New South Wales Department of Health ·
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Multiple Myeloma Research and Treatments, and Lung Cancer Treatments and Mutations.
h-index
23
citations
8,297
works
70
NIH funding
primary concept
email

Recent publications

Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies
Proceedings of the National Academy of Sciences 2025cited by 6position: middledoi
Human genomic DNA is widely interspersed with i-motif structures
The EMBO Journal 2024cited by 33position: middledoi
Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients
Nature Communications 2023cited by 39position: middledoi
Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia
Nature Microbiology 2022cited by 56position: middledoi
Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability
Immunity 2021cited by 54position: middledoi
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Nature Cancer 2020cited by 102position: middledoi
Neoantigen-directed immune escape in lung cancer evolution
Nature 2019cited by 968position: middledoi
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Science 2016cited by 3,084position: middledoi
The Heterogeneity of Ly6Chi Monocytes Controls Their Differentiation into iNOS+ Macrophages or Monocyte-Derived Dendritic Cells
Immunity 2016cited by 286position: middledoi
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
The Journal of Experimental Medicine 2013cited by 1,443position: middledoi
Enhanced cross‐priming of naive <scp>CD</scp>8<sup>+</sup><scp>T</scp> cells by dendritic cells treated by the <scp>IM</scp>i<scp>D</scp>s<sup>®</sup> immunomodulatory compounds lenalidomide and pomalidomide
Immunology 2013cited by 85position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Sergio A. Quezada · Cancer Research UK2 papers (2013–2016)Frederick Arce · University College London1 papers (2013–2013)Stéphanie Hugues · University of Geneva1 papers (2016–2016)Jessica A. Kretzmann · Technical University of Munich1 papers (2024–2024)Thibaut Perchet · Institut Pasteur1 papers (2016–2016)Frédéric Geissmann · Memorial Sloan Kettering Cancer Center1 papers (2016–2016)Marie‐Christine Labarthe · University of York1 papers (2013–2013)Mahdi Zeraati · UNSW Sydney1 papers (2024–2024)Ana‐Maria Lennon‐Duménil · Institut Pasteur1 papers (2016–2016) · 1 papers (2013–2013)Karl S. Peggs · CRUK Lung Cancer Centre of Excellence1 papers (2013–2013)Rajen Patel · University of Ottawa1 papers (2016–2016)Daniel Christ · UNSW Sydney1 papers (2024–2024)Cristian David Peña Martinez · UNSW Sydney1 papers (2024–2024)Michel C. Nussenzweig · Rockefeller University1 papers (2016–2016)Prokar Dasgupta · University of Silesia in Katowice1 papers (2013–2013)Nicole M. Smith · The University of Western Australia1 papers (2024–2024)Jeffrey V. Ravetch · Rockefeller University1 papers (2013–2013) · 1 papers (2016–2016)Brian Gloss · Westmead Institute1 papers (2024–2024)